AbbVie Inc. $ABBV Shares Bought by Empirical Asset Management LLC

Empirical Asset Management LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,372 shares of the company’s stock after acquiring an additional 6,986 shares during the period. Empirical Asset Management LLC’s holdings in AbbVie were worth $2,402,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the 2nd quarter valued at approximately $28,000. Redmont Wealth Advisors LLC bought a new stake in AbbVie during the 3rd quarter valued at $41,000. Financial Gravity Companies Inc. acquired a new position in AbbVie during the 2nd quarter worth $36,000. Finally, Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter worth $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two active pharmaceutical ingredient (API) plants at its North Chicago campus to support neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029, strengthening domestic supply and “Made in U.S.” manufacturing capacity. Article Title
• Positive Sentiment: FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line, all‑oral, fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully support oncology revenue growth. Article Title
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a catalyst that can attract buyers. Article Title
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in bipolar I disorder, a data point that supports the product’s real‑world evidence but is unlikely to move near‑term revenue materially. Article Title
• Neutral Sentiment: Analysts have modestly updated fair‑value models (example: a small move to ~$248.29), reflecting mixed views — positive readthroughs on pipeline and immunology assets offset by caution on execution. Article Title
• Negative Sentiment: Investor concerns about competitive pressure in key franchises and execution risk (integration, manufacturing ramp timelines, and maintaining growth after major product lifecycles) are being highlighted in coverage and may be prompting profit‑taking. Article Title

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Morgan Stanley boosted their target price on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Down 0.5%

Shares of NYSE:ABBV opened at $228.44 on Wednesday. The company’s fifty day moving average is $224.17 and its two-hundred day moving average is $222.67. The company has a market cap of $403.92 billion, a P/E ratio of 96.80, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.